Ligand Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, LGND, Ligand Pharmaceuticals Inc, priceseries

Ligand Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
96.92
Close
97.91
High
100.23
Low
96.92
Previous Close
96.92
Daily Price Gain
0.99
YTD High
156.27
YTD High Date
Jan 3, 2022
YTD Low
88.50
YTD Low Date
Feb 24, 2022
YTD Price Change
-53.65
YTD Gain
-35.40%
52 Week High
172.19
52 Week High Date
Mar 15, 2021
52 Week Low
88.50
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-41.43
52 Week Gain
-29.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 9. 2018
144.25
Jan 31. 2018
159.75
15 Trading Days
10.74%
Link
LONG
Mar 2. 2018
159.01
Mar 16. 2018
171.08
10 Trading Days
7.59%
Link
LONG
May 9. 2018
168.99
Jun 11. 2018
192.41
22 Trading Days
13.86%
Link
LONG
Jun 27. 2018
198.60
Jul 27. 2018
222.74
21 Trading Days
12.16%
Link
LONG
Mar 13. 2019
116.31
Mar 27. 2019
122.26
10 Trading Days
5.12%
Link
LONG
Sep 10. 2019
90.19
Sep 24. 2019
100.20
10 Trading Days
11.10%
Link
LONG
Feb 5. 2020
92.19
Feb 28. 2020
97.06
16 Trading Days
5.28%
Link
LONG
Apr 3. 2020
73.23
Apr 28. 2020
93.58
16 Trading Days
27.79%
Link
LONG
Dec 9. 2020
90.25
Dec 29. 2020
99.10
13 Trading Days
9.81%
Link
LONG
Jan 6. 2021
102.78
Feb 11. 2021
186.51
25 Trading Days
81.46%
Link
LONG
Jun 10. 2021
120.83
Jun 30. 2021
132.15
14 Trading Days
9.37%
Link
LONG
Aug 27. 2021
114.33
Sep 14. 2021
132.51
11 Trading Days
15.90%
Link
LONG
Oct 20. 2021
131.40
Nov 23. 2021
161.14
24 Trading Days
22.63%
Link
Company Information
Stock Symbol
LGND
Exchange
NasdaqGM
Company URL
http://www.ligand.com
Company Phone
858-550-7500
CEO
John L. Higgins
Headquarters
California
Business Address
3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000886163
About

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading